Personalized medical care
because you're unique

Like snow flakes, no two individuals are identical. Our genetic makeup drives our uniqueness. We believe that medical care should reflect that uniqueness. Our products identify disease predisposition as a first step toward personalized health care.

Welcome to ArcticDx Inc.

ArcticDx Inc. is a private Canadian company that is developing two molecular tests, Colo Risk™, for Colorectal Cancer and Macula Risk™ for Age-related Macular Degeneration.

News & Events

Apr 16, 2008: ArcticDx Licenses exclusive rights to ARMS2 genetic polymorphisms from Vanderbilt University

ArcticDx Inc has closed license agreements with Vanderbilt University for its rights to an International Patent Application entitled 'Genetic Variants Increase the Risk of Age-Related Macular Degeneration'. This patent application(s) protects the utility of a coding change in LOC387715 at rs10490924. The invention and the patent application include a direct link to these variants with smoking… more

Apr 01, 2008: ArcticDx Licenses exclusive rights to C3 genetic polymorphism from Cambridge Enterprise Limited

ArcticDx Inc. has taken an exclusive license to a critical genetic polymorphism related to the genetic diagnosis of Age-related Macular Degeneration. The licensor, Cambridge Enterprise Limited is wholly owned by the Chancellor, Masters and Scholars of the University of Cambridge… more